MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

Начало・Списък с акции・Lyell Immunopharma Inc

Lyell Immunopharma Inc

Затворен

0.42 -2.33

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.41

Максимум

0.45

Ключови измерители
By Trading Economics
Приходи	-147M -192M
Продажби	-23K 11K
EPS	-0.172
Марж на печалбата	-1,744,863.636
Служители	300
EBITDA	-12M -58M

Препоръки
By TipRanks
Препоръки	Продай
12-месечна прогноза	+122.22% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-87M 129M
Предишно отваряне	2.75
Предишно затваряне	0.42

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

0.429 / 0.4588 Подкрепа & съпротива

Lyell Immunopharma Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.04.2025 г., 23:53 ч. UTC

Горещи акции

Stocks to Watch: Starbucks, Snap, Super Micro Computer, Seagate Technology

29.04.2025 г., 23:06 ч. UTC

Печалби

Prudential PLC 1Q New Business Profit Increases by 12%

29.04.2025 г., 23:00 ч. UTC

Печалби

America Movil's Posts Rise in 1Q Profit, Revenue

30.04.2025 г., 00:00 ч. UTC

Топ новини

Buffett's 'Woodstock for Capitalists' Draws Admirers From Around the Globe -- WSJ

29.04.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About U.S. Tariffs Ebb -- Market Talk

29.04.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Consolidates; Signs of Easing in U.S. Tariffs' Impact May Weigh -- Market Talk

29.04.2025 г., 23:41 ч. UTC

Печалби

China Minsheng Banking 1Q Net Interest Income CNY24.87B Vs. CNY24.26B>1988.HK

29.04.2025 г., 23:41 ч. UTC

Печалби

China Minsheng Banking 1Q Operating Income CNY36.81B Vs. CNY34.27B>1988.HK

29.04.2025 г., 23:41 ч. UTC

Печалби

China Minsheng Banking 1Q Net CNY12.74B Vs. Net CNY13.45B >1988.HK

29.04.2025 г., 23:24 ч. UTC

Печалби

China Vanke 1Q Rev CNY37.99B Vs. CNY61.59B >000002.SZ

29.04.2025 г., 23:24 ч. UTC

Печалби

China Vanke: Increase in Investment Losses Also Hurt Results >000002.SZ

29.04.2025 г., 23:24 ч. UTC

Печалби

China Vanke 1Q Loss CNY6.25B Vs. Loss CNY361.97M >000002.SZ

29.04.2025 г., 23:24 ч. UTC

Печалби

China Vanke: Singificant Decline in Property Sales Weighed on Results >000002.SZ

29.04.2025 г., 23:24 ч. UTC

Печалби

China Vanke 1Q Loss Widened Significantly >000002.SZ

29.04.2025 г., 23:15 ч. UTC

Топ новини

UPS to Cut 20,000 Jobs After Amazon Breakup -- 2nd Update

29.04.2025 г., 23:14 ч. UTC

Печалби

China Eastern Airlines 1Q Loss CNY995.0M Vs. Loss CNY803.0M >0670.HK

29.04.2025 г., 23:14 ч. UTC

Печалби

China Eastern Airlines: Increased Competition in the Aviation Market Hurt Results >0670.HK

29.04.2025 г., 23:14 ч. UTC

Печалби

China Eastern Airlines 1Q Rev CNY33.41B Vs. CNY33.19B >0670.HK

29.04.2025 г., 23:14 ч. UTC

Печалби

China Eastern Airlines 1Q Loss Widened >0670.HK

29.04.2025 г., 23:11 ч. UTC

Печалби

China Southern Airlines Swung to Loss in 1Q>1055.HK

29.04.2025 г., 23:11 ч. UTC

Печалби

China Southern Airlines 1Q Rev CNY43.41B Vs. CNY44.60B >1055.HK

29.04.2025 г., 23:11 ч. UTC

Печалби

China Southern Airlines: Shift in Traveler Demographics, Competition From High-Speed Rail Networks Also Hurt Results >1055.HK

29.04.2025 г., 23:11 ч. UTC

Печалби

China Southern Airlines 1Q Loss CNY747.0M Vs. Net CNY756.0M >1055.HK

29.04.2025 г., 23:11 ч. UTC

Печалби

China Southern Airlines: CNY Depreciation, Global Supply Chain Constraints Among Factors Weighing on Results >1055.HK

29.04.2025 г., 23:07 ч. UTC

Печалби

Air China 1Q Rev CNY40.02B Vs. CNY40.07B >0753.HK

29.04.2025 г., 23:07 ч. UTC

Печалби

Air China 1Q Losses Widened>0753.HK

29.04.2025 г., 23:07 ч. UTC

Печалби

Air China 1Q Loss CNY2.04B Vs. Loss CNY1.67B >0753.HK

29.04.2025 г., 23:02 ч. UTC

Печалби

COSCO SHIPPING Energy Transportation: Weaker Earnings In International Oil Tanker Fleet Business Weighed on Results>1138.HK

29.04.2025 г., 23:02 ч. UTC

Печалби

COSCO SHIPPING Energy Transportation 1Q Net CNY707.70M Vs. Net CNY1.24B >1138.HK

29.04.2025 г., 23:02 ч. UTC

Печалби

COSCO SHIPPING Energy Transportation 1Q Rev CNY5.75B Vs. CNY5.84B >1138.HK

Сравнение с други в отрасъла

Ценова промяна

Lyell Immunopharma Inc Прогноза

Ценова цел

By TipRanks

122.22% нагоре

12-месечна прогноза

Среден 1 USD 122.22%

Висок 1 USD

Нисък 1 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Lyell Immunopharma Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Продай

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Lyell Immunopharma Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.429 / 0.4588Подкрепа & съпротива

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

There are no events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.